ABSTRACT. Mitochondrial DNA mutations that lead to mitochondrial dysfunction have long been proposed to play important roles in the development of pancreatic cancer. Of these, alterations to mitochondrial tRNA genes constitute the largest group. Most recently, a variation at position 12307 in the gene encoding tRNA Leu(CUN) has been reported to be associated with this disease. However, the molecular mechanism underlying this relationship remains poorly understood. To assess this association, we evaluated this variant by evolutionary conservation analysis, measurements of allelic frequencies among control subjects, and use of several bioinformatic tools to estimate potential structural and functional alterations. We found this residue to have a high conservation index; however, the presence of the A12307G variation in control subjects revealed by a literature search suggested it to be common in human populations. Moreover, RNAfold results showed that this variant did not alter the secondary structure of tRNA Leu(CUN) . Through the application of a pathogenicity scoring system, this variant was determined to be a "neutral polymorphism," with a score of only 4 points based on current data. Thus, the contribution of the
INTRODUCTION
Pancreatic cancer is the fourth leading cause of cancer-related mortality among men and women in the USA, with 43,140 new cases and 36,800 deaths having been reported in 2010 (American Cancer Society, 2010) . The five-year survival rate for patients suffering from this cancer is a mere 5%, emphasizing the need for a detailed understanding of the molecular changes underlying this disease, and the application of this knowledge to early diagnosis and therapeutic intervention. It is now generally believed that genetic variants play important roles in pancreatic cancer, for example, polymorphisms in NAT 2 and XRCC4 genes are believed to be associated with this malignancy Liang et al., 2015) . Nevertheless, few studies have focused on the relationship between mitochondrial DNA (mtDNA) mutations and pancreatic cancer.
As early as 1956, Warburg (1956) proposed that an important contributing factor to carcinogenesis was the alteration of oxidative phosphorylation (OXPHOS) owing to injured mitochondria. Human mtDNA is a double-stranded, circular DNA molecule of 16.5 kb, including genes encoding electron transport chain proteins (complexes I-IV), ATP synthase (OXPHOS complex V), 2 rRNAs, and 22 tRNAs, and featuring a D-loop region (Wallace and Chalkia, 2013) . Mitochondrial dysfunction is a common feature of cancer cells. Somatic mutations of mtDNA have been reported in a variety of cancers, including pancreatic cancer (Jones et al., 2001; Taylor and Turnbull, 2005; Navaglia et al., 2006) . These sequence variations, such as intragenic deletions and missense mutations, have been identified in nearly every type of tumor.
Most recently, Lam et al. (2012) investigated sequence variants in the mitochondrial genomes of 286 pancreatic cancer patients and 283 healthy controls using the GeneChip CustomSeq resequencing array. Based on their findings, a homoplasmic A12307G variation in the gene encoding tRNA Leu(CUN) was established as being associated with pancreatic cancer (P < 0.05). However, to date, little is known regarding the pathogenic role of the A12307G variant. In this study, we used a phylogenetic approach to determine the deleterious influence of this sequence variation and examined its potential functional effects.
MATERIAL AND METHODS
To reevaluate the dataset, we extracted clinical, genetic, and molecular data from Lam et al. (2012) . For comparison, we incorporated previous publications (if any) concerning occurrence of the A12307G variant, to evaluate its frequency and pathogenicity in relation to mitochondrial disease.
To understand the molecular mechanism of this variation in cancer, we first performed a phylogenetic evaluation to calculate the corresponding conservation index (CI), as evolutionary conservation analysis is important in determining the pathogenicity of a candidate tRNA mutation. In addition, A12307G allele frequencies were examined by using the MITOMASTER program to screen mitochondrial genome sequence variations in the National Center for Biotechnology Information database (www.ncbi.nlm.nih.gov; Brandon et al., 2009) .
Effects of the A12307G variant on the secondary structure of tRNA Leu(CUN) were estimated with the RNAfold program, which predicts the minimum free energy (MFE) of a tRNA from its sequence (Gruber et al., 2008) . Finally, we applied a pathogenicity scoring system to the A12307G sequence variation. Based on this, a variant is classified as a "polymorphism" if scoring < 6, "possibly pathogenic" with a score between 7 and 10, and "pathogenic" if it scores > 11 (Yarham et al., 2010 (Yarham et al., , 2011 . Lam et al. (2012) recruited 532 pancreatic cancer patients and 1701 controls to screen common and rare mutations in mitochondrial genomes. However, the selection of sampling method was rather problematic, as the frequency of mtDNA mutations may not be the same in tissues as it is in blood. Thus, cancer tissue specimens should be used, rather than blood samples. From the data, we observed that the A12307G variation was detected in 34 healthy control subjects, with an allele frequency of 13.7%, suggesting that it is common in humans.
RESULTS

Diagnostic pitfall of the A12307G variant
MITOMASTER results
To assess A12307G allelic frequencies, we used the MITOMASTER program to evaluate reported records in GenBank (Brandon et al., 2009 ). We identified three mtDNA genome sequences containing the A12307G variant in PubMed Central, with accession Nos. JQ706026.1, JQ706032.1, and JQ706045.1 (Table 1) . After careful review, we noticed that the complete set of mtDNA sequence variations belonged to human mitochondrial haplogroup U2d (van Oven and Kayser, 2009) . Of these variants, some are apparently pathogenic. For example, the ND2 G5460A mutation is considered to be associated with metabolic disease (Saxena et al., 2006) , while the A to G transition at position 8296 in the gene encoding tRNA Lys has been implicated in mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes, and myoclonic epilepsy with ragged-red fibers (Arenas et al., 1999; Sakuta et al., 2002) . The common T16189C variant in the D-loop region has been found to play an important role in the development of metabolic syndrome (Palmieri et al., 2011) . Moreover, the homoplasmic CYTB T15287C mutation has been reported to increase the penetrance and expressivity of aminoglycoside-induced and non-syndromic hearing loss (Janssen et al., 2006) . Finally, the A11467G and G12372A mutations identified have been shown to alter brain pH (Rollins et al., 2009 ). Thus, it appears that while other mutations may play important roles in pancreatic cancer, the A12307G variant does not.
Evolutionary conservation analysis of the A12307G variant
For an insight into the pathogenicity of the A12307G variant, we analyzed the CI of this residue. As shown in Figure 1 , this position was highly conserved across different species (CI = 90%). A73G  T152C  T152C  T152C  A188G  T199C  T199C  T199C  T471C  T471C  T471C  A16051G  A16051G  A16051G  T16093C  A16183C  A16183C  C16148T  T16189C  T16189C  C16184T  C16234T  C16234T  T16189C  C16266T  C16294T  C16234T  C16294T  T16519C  C16294T  T16519C  12S rRNA  A750G  T16342C  12S rRNA  A750G  A1438G  12S rRNA  A750G  T1040C  16S rRNA  T1700C  A1438G  16S rRNA  T1700C  A1811G  16S rRNA  T1700C  A1811G  A2706G  A1811G  A2706G  ND1  C4025T  A2706G  ND1  C4025T  ND2  A4769G  ND1  C4025T  ND2  A4769G  G5147A  ND2  A4769G  CO1  G6023A  G5460A  CO1  C7028T  C7028T  CO1  T6956C  A6/A8  G8557A  A7277G  C7028T  A6  A8860G  CO2  A7894G  tRNA Lys  A8296G  A8938G  A6  A8860G  A6  A8860G  A8982G  A8938G  A8938G  ND4  A11467G  ND4  A11467G  ND4  A11467G  G11719A  G11719A  G11719A  A11893G  A11893G  A11893G tRNA Leu(CUN) A12307G tRNA Leu(CUN) A12307G tRNA Leu (CUN)  A12307G  ND5  G12372A  ND5  G12372A  ND5  G12372A  G12651A  CytB  C14766T  T13789C  CytB  C14766T  A14926G  CytB  C14766T  A14926G  T15287C  A14926G  A15244G  A15326G  A15326G A15326G G15883A 
MFE prediction
We further utilized the RNAfold web server to characterize the potential effect of the A12307G variant on thermodynamic changes to tRNA Leu(CUN) (Gruber et al., 2008) . The MFE of the 12307A and 12307G alleles was found to be -16.01 and -15.98 kcal/mol, respectively.
We also analyzed MFE structures generated from wild type and A12307G mutant sequences. As shown in Figure 2 , it was quite obvious that this variant did not induce a change in the MFE structure of tRNA Leu(CUN) , suggesting that it may not play an important role in pancreatic cancer. 
Pathogenicity scoring system
According to a revised pathogenicity scoring system (Yarham et al., 2010 (Yarham et al., , 2011 , the A12307G variant was classified as a "neutral polymorphism," with a total score of 4 points ( Table 2) . Table 2 . Pathogenicity scoring system used to assess the A12307G mutation. 
DISCUSSION
Cancer is considered to comprise a heterogeneous set of divergent molecular and cellular features, and increasing evidence suggests that mitochondria play a key role in carcinogenesis (Chatterjee et al., 2006; Hu et al., 2015) . Mutations in mtDNA may lead to mitochondrial dysfunction and the metabolic reprogramming of malignant cells, leading to the modulation of cellular processes involved in the initiation and progression of cancer. Somatic mtDNA mutations have been identified in many human tumors and are common in pancreatic cancer (Jones et al., 2001; Navaglia et al., 2006) . Some of these mutations are localized in OXPHOS-complex genes and the D-loop region, while others occur in mt-tRNA genes. Mutations in these latter have an impact on secondary and tertiary tRNA structure, and may cause translational and transcriptional defects, inducing mitochondrial respiratory chain dysfunction.
mt-tRNA point mutations have been associated with a diverse range of clinical phenotypes, including epilepsy, deafness, diabetes, cardiomyopathy, and encephalopathy (Florentz et al., 2003; Yarham et al., 2010) . To date, over 200 mt-tRNA mutations have been linked to mitochondrial disease, but sufficient evidence to justify a classification of "definitely pathogenic" exists for less than half of these (Yarham et al., 2011) , demonstrating the difficulties faced when characterizing potentially pathogenic variants. Distinguishing mttRNA polymorphisms from mutations is important, since failure to do so will inevitably lead to poor diagnostic and genetic advice.
In this study, we reanalyzed the possible role of the tRNA Leu(CUN) A12307G variant in pancreatic cancer through the application of bioinformatics and phylogenetic conservation analysis. We notice that the homoplasmic A12307G variant is localized at position 43 in the anticodon stem of tRNA Leu(CUN) (Figure 3 ). It is generally believed that each cell contains hundreds to thousands of mtDNA copies. Once a pathogenic mutation occurs, a population of this pathogenic mtDNA coexists with wild-type mtDNA, a condition known as heteroplasmy. When the frequency of pathogenic mtDNA in a cell increases and exceeds a threshold, a clinical phenotype arises. This observation highlights the importance of heteroplasmic mtDNA mutations in clinical diseases, and suggests that the homoplasmic A12307G variant may not be involved in the pathogenesis of pancreatic cancer. To assess the potential deleterious role of this variant, we applied the following criteria: a pathogenic mutation should be 1) present in < 1% of healthy controls; 2) affect a residue with a CI > 75%, as proposed by Ruiz-Pesini and Wallace (2006); 3) potentially induce structural and functional alterations; and 4) score highly on the pathogenicity scoring system. We found that the A12307G variant was present in healthy controls at a frequency of 13.7%, and RNAfold results showed that it did not alter the MFE structure of tRNA Leu(CUN) . In addition, this mutation was assigned only 4 points by the pathogenicity scoring system employed, being categorized as a "neutral polymorphism" based on current data. Thus, the role of the A12307G variant in pancreatic cancer needs to be addressed in further experimental investigations.
